25(top 2%)
papers
1.1K(top 2%)
citations
12(top 2%)
h-index
19(top 2%)
g-index
26
all documents
1.2K
doc citations
430
citing journals

Top Articles

#TitleJournalYearCitations
1Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramAnnals of Oncology2018246
2Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal AdenocarcinomaJAMA Oncology2017221
3An international study to increase concordance in Ki67 scoringModern Pathology2015195
4Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaborationNpj Breast Cancer2016109
5A Framework for Biobank SustainabilityBiopreservation and Biobanking2014105
6An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancerModern Pathology201978
7Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancerPLoS Computational Biology201951
8ISOWN: accurate somatic mutation identification in the absence of normal tissue controlsGenome Medicine201744
9Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramModern Pathology201732
10Proximity ligation assays for isoform‐specific Akt activation in breast cancer identify activated Akt1 as a driver of progressionJournal of Pathology201229
11Abstract S6-05: Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program201520
12Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistanceBMC Cancer201416
13A Practical Tool for Modeling Biospecimen User FeesBiopreservation and Biobanking201415
14Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trialBritish Journal of Cancer20136
15A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trialsOncotarget20156
16Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancerBreast Cancer Research and Treatment20145
17Tumour infiltrating lymphocytes and stromal CD68 in early stage HER2 positive breast cancerJournal of Clinical Pathology20165
18Expression of activated type I receptor tyrosine kinases in early breast cancerBreast Cancer Research and Treatment20123
19Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIESBreast Cancer Research and Treatment20183
20A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trialOncotarget20162
21Abstract P4-11-10: Time dependence of biomarkers: Non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer20151
22Abstract P4-11-09: Comparison of immunohistochemical residual risk panels to predict risk in early breast cancers treated with endocrine therapy20151
23Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019)20150
24Abstract P4-11-04: Intrinsic subtypes and BCL2 as predictive and prognostic biomarkers in the TACT2 trial (CRUK/05/019)20150
25Abstract P3-07-08: Comparison of MammaTyper® RT-qPCR based subtyping with simulated breast cancer prognostic signatures20200